Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.19 USD | -2.41% | +16.14% | +56.88% |
May. 20 | Nurix Therapeutics Names New Board Chair | MT |
May. 14 | Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+56.88% | 960M | C | ||
+9.58% | 115B | B+ | ||
+12.41% | 107B | B+ | ||
-2.59% | 21.6B | B | ||
-12.38% | 22.31B | B+ | ||
-5.29% | 19.19B | A- | ||
-3.35% | 18.23B | B | ||
-38.57% | 17.62B | A- | ||
+7.51% | 14.26B | C+ | ||
+35.67% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NRIX Stock
- Ratings Nurix Therapeutics, Inc.